Verona Pharma PLC
VRNA68.915USD
+3.455+5.28%
交易中 （美东）报价延迟15分钟
46.66B总市值
亏损市盈率 TTM
关于 Verona Pharma PLC 公司
Verona Pharma Plc 是一家总部位于英国的生物制药公司。该公司专注于开发和商业化用于治疗未满足医疗需求的呼吸系统疾病的疗法。其候选产品恩替芬碱是一种研究性吸入小分子酶，可双重抑制酶的磷酸二酯酶 3 和 4 (PDE3 和 PDE4)，将支气管扩张剂和非甾体抗炎活性结合在一个化合物中。该公司致力于开发用于治疗慢性阻塞性肺病 (COPD) 的吸入恩替芬碱。该公司的另外两种恩替芬碱配方正处于用于治疗 COPD 的 II 期开发阶段：干粉吸入器 (DPI) 和加压定量吸入器 (pMDI)。该公司的全资子公司是 Verona Pharma, Inc.
公司简介
公司代码VRNA
公司名称Verona Pharma PLC
上市日期Mar 30, 2005
成立日期2005
CEODr. David S. Zaccardelli
员工数量209
证券类型Depository Receipt
年结日Mar 30
公司地址Riverside
城市LONDON
上市交易所NASDAQ Global Market Consolidated
国家United Kingdom
邮编SE1 2RE
电话442032834200
网址https://www.veronapharma.com/
公司代码VRNA
上市日期Mar 30, 2005
成立日期2005
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. David S. Zaccardelli
Dr. David S. Zaccardelli
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
11.51M
+1.80K%
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Chief Financial Officer
Chief Financial Officer
10.60M
+4.02K%
Ms. Claire Louise Poll
Ms. Claire Louise Poll
General Counsel
General Counsel
541.81K
--
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Non-Executive Independent Director
Non-Executive Independent Director
74.44K
+700.00%
Dr. Mahendra G. Shah, Ph.D.
Dr. Mahendra G. Shah, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
73.08K
+700.00%
Ms. Lisa Deschamps
Ms. Lisa Deschamps
Non-Executive Independent Director
Non-Executive Independent Director
70.32K
+700.00%
Mr. Michael Austwick
Mr. Michael Austwick
Non-Executive Director
Non-Executive Director
--
--
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Christina Ackermann
Ms. Christina Ackermann
Non-Executive Director
Non-Executive Director
--
--
Dr. Martin William Edwards, M.D.
Dr. Martin William Edwards, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. David S. Zaccardelli
Dr. David S. Zaccardelli
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
11.51M
+1.80K%
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Chief Financial Officer
Chief Financial Officer
10.60M
+4.02K%
Ms. Claire Louise Poll
Ms. Claire Louise Poll
General Counsel
General Counsel
541.81K
--
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Non-Executive Independent Director
Non-Executive Independent Director
74.44K
+700.00%
Dr. Mahendra G. Shah, Ph.D.
Dr. Mahendra G. Shah, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
73.08K
+700.00%
Ms. Lisa Deschamps
Ms. Lisa Deschamps
Non-Executive Independent Director
Non-Executive Independent Director
70.32K
+700.00%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 3月28日 周五
更新时间: 3月28日 周五
持股股东
股东类型
持股股东
股东统计
占比
Zaccardelli (David S)
13.55%
Hahn (Mark W)
12.48%
Perceptive Advisors LLC
7.52%
New Enterprise Associates (NEA)
4.81%
Frazier Life Sciences Management, L.P.
3.98%
Other
57.67%
持股股东
股东统计
占比
Zaccardelli (David S)
13.55%
Hahn (Mark W)
12.48%
Perceptive Advisors LLC
7.52%
New Enterprise Associates (NEA)
4.81%
Frazier Life Sciences Management, L.P.
3.98%
Other
57.67%
股东类型
股东统计
占比
Individual Investor
35.16%
Investment Advisor/Hedge Fund
22.11%
Hedge Fund
21.55%
Investment Advisor
15.58%
Private Equity
11.64%
Venture Capital
7.78%
Research Firm
2.44%
Family Office
1.04%
Bank and Trust
0.28%
机构持股
更新时间: 3月4日 周二
更新时间: 3月4日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q1
341
98.98M
116.47%
+16.60M
2024Q4
326
71.46M
84.46%
-16.29M
2024Q3
290
72.06M
88.66%
-13.37M
2024Q2
265
71.81M
88.57%
-10.49M
2024Q1
244
72.12M
89.24%
-7.07M
2023Q4
230
69.67M
87.15%
-7.79M
2023Q3
210
67.04M
84.35%
-7.14M
2023Q2
205
65.57M
82.53%
-8.85M
2023Q1
188
68.22M
86.63%
-3.18M
2022Q4
162
65.88M
87.36%
-542.66K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Zaccardelli (David S)
11.51M
13.55%
+10.91M
+1.80K%
Mar 01, 2025
Hahn (Mark W)
10.60M
12.48%
+10.34M
+4.02K%
Mar 01, 2025
Perceptive Advisors LLC
6.39M
7.52%
+76.17K
+1.21%
Dec 31, 2024
New Enterprise Associates (NEA)
4.08M
4.81%
-1.50M
-26.86%
Jan 16, 2025
Frazier Life Sciences Management, L.P.
3.38M
3.98%
--
--
Dec 31, 2024
Ali (Behbahani)
3.19M
3.76%
+3.19M
--
Jan 16, 2025
Eventide Asset Management, LLC
3.13M
3.69%
+706.28K
+29.11%
Dec 31, 2024
Maverick Capital, Ltd.
3.13M
3.68%
-1.09M
-25.79%
Dec 31, 2024
Wellington Management Company, LLP
3.03M
3.56%
+1.15M
+61.03%
Dec 31, 2024
Vivo Capital, LLC
2.28M
2.69%
-1.27M
-35.66%
Dec 31, 2024
查看更多
持股ETF
更新时间: 4月6日 周日
更新时间: 4月6日 周日
机构名称
占比
AdvisorShares Dorsey Wright ADR ETF
6.2%
ALPS Medical Breakthroughs ETF
4.7%
ProShares Ultra Nasdaq Biotechnology
0.5%
First Trust IPOX Europe Equity Opportunities ETF
0.49%
Invesco Nasdaq Biotechnology ETF
0.49%
iShares Biotechnology ETF
0.3%
Goldman Sachs Innovate Equity ETF
0.16%
Eventide US Market ETF
0.09%
Fidelity Nasdaq Composite Index ETF
0.01%
First Trust Long/Short Equity ETF
0%
查看更多
AdvisorShares Dorsey Wright ADR ETF
占比6.2%
ALPS Medical Breakthroughs ETF
占比4.7%
ProShares Ultra Nasdaq Biotechnology
占比0.5%
First Trust IPOX Europe Equity Opportunities ETF
占比0.49%
Invesco Nasdaq Biotechnology ETF
占比0.49%
iShares Biotechnology ETF
占比0.3%
Goldman Sachs Innovate Equity ETF
占比0.16%
Eventide US Market ETF
占比0.09%
Fidelity Nasdaq Composite Index ETF
占比0.01%
First Trust Long/Short Equity ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据